Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind study to assess the efficacy and safety of clazosentan in reducing cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage treated by surgical clipping

Next Previous
X
Search
Trial Profile

A double-blind study to assess the efficacy and safety of clazosentan in reducing cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage treated by surgical clipping

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clazosentan (Primary)
  • Indications Cerebral vasospasm
  • Focus Registrational; Therapeutic Use
  • Acronyms Clipping study
  • Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals

    • Most Recent Events

    • 07 Dec 2023 According to an Idorsia Pharmaceuticals media release, based on scientific and clinical data from an extensive Japanese Phase 3 program (JapicCTI163369,JapicCTI163368), the PIVLAZ (clazosentan sodium) 150 mg has received marketing approval from the Ministry of Food and Drug Safety (MFDS) in South Korea for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing.
    • 01 Dec 2022 Results of pooled analysis from two studies: apicCTI-163368 and JapicCTI-163369 published in the Journal of Neurosurgery
    • 26 Apr 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top